Liver disease in cystic fibrosis.
作者信息
Tanner M S, Taylor C J
机构信息
Department of Paediatrics, University of Sheffield.
出版信息
Arch Dis Child. 1995 Apr;72(4):281-4. doi: 10.1136/adc.72.4.281.
Abstract
摘要
相似文献
1
Liver disease in cystic fibrosis.囊性纤维化中的肝脏疾病
Arch Dis Child. 1995 Apr;72(4):281-4. doi: 10.1136/adc.72.4.281.
2
[Hepatobiliary disease in cystic fibrosis].[囊性纤维化中的肝胆疾病]
Med Clin (Barc). 1998 Sep 19;111(8):302-6.
3
Current Treatment Options for Cystic Fibrosis-Related Liver Disease.囊性纤维化相关性肝病的治疗选择。
Int J Mol Sci. 2020 Nov 14;21(22):8586. doi: 10.3390/ijms21228586.
4
Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.血清胆汁酸及熊去氧胆酸治疗囊性纤维化相关肝病
Eur J Gastroenterol Hepatol. 1996 May;8(5):477-83.
5
Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease.对患有囊性纤维化及相关肝病的患者使用熊去氧胆酸治疗后肝胆排泄功能改善的闪烁扫描记录。
Hepatology. 1992 Apr;15(4):677-84. doi: 10.1002/hep.1840150421.
6
Liver and biliary problems in cystic fibrosis.
Semin Liver Dis. 1998;18(3):227-35. doi: 10.1055/s-2007-1007159.
7
Liver and biliary problems in cystic fibrosis.囊性纤维化中的肝脏和胆道问题。
J R Soc Med. 1992;85 Suppl 19(Suppl 19):20-4.
8
Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study.熊去氧胆酸治疗囊性纤维化相关肝病：一项剂量反应研究。
Hepatology. 1992 Oct;16(4):924-30. doi: 10.1002/hep.1840160412.
9
Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.熊去氧胆酸治疗与囊性纤维化相关的肝病：一项双盲多中心试验。意大利囊性纤维化熊去氧胆酸研究小组。
Hepatology. 1996 Jun;23(6):1484-90. doi: 10.1002/hep.510230627.
10
Mild pulmonary, but severe hepatic disease in a cystic fibrosis patient homozygous for a frameshift mutation in the regulatory domain of the CFTR.一名囊性纤维化患者，其CFTR调节域的移码突变纯合子，肺部疾病较轻，但肝脏疾病严重。
J Med Genet. 1993 May;30(5):446. doi: 10.1136/jmg.30.5.446.
引用本文的文献
1
Aetiopathogenesis of liver changes in the course of cystic fibrosis, considering disturbances of the bile acid profile as well as genetic and immunological factors.囊性纤维化病程中肝脏变化的病因学，考虑胆汁酸谱紊乱以及遗传和免疫因素。
Prz Gastroenterol. 2013;8(5):290-4. doi: 10.5114/pg.2013.38730. Epub 2013 Oct 28.
2
A new metabolomics analysis technique: steady-state metabolic network dynamics analysis.一种新的代谢组学分析技术：稳态代谢网络动力学分析。
J Bioinform Comput Biol. 2012 Feb;10(1):1240003. doi: 10.1142/S0219720012400033.
3
The role of abdominal ultrasound in the diagnosis, staging and management of cystic fibrosis liver disease.腹部超声在囊性纤维化肝病的诊断、分期及管理中的作用。
J R Soc Med. 2005;98 Suppl 45(Suppl 45):17-27.
4
The gallbladder and biliary tract in cystic fibrosis.囊性纤维化中的胆囊和胆道。
Curr Gastroenterol Rep. 2005 May;7(2):147-53. doi: 10.1007/s11894-005-0053-6.
5
The evolution of liver disease in cystic fibrosis.
Arch Dis Child. 1999 Aug;81(2):129-32. doi: 10.1136/adc.81.2.129.
6
Retrospective review of cystic fibrosis presenting as infantile liver disease.对表现为婴儿期肝病的囊性纤维化进行回顾性研究。
Arch Dis Child. 1999 Aug;81(2):125-8. doi: 10.1136/adc.81.2.125.
7
Ursodeoxycholic acid in cystic fibrosis-related liver disease: a systematic review.熊去氧胆酸在囊性纤维化相关肝病中的应用：一项系统评价
J R Soc Med. 1997;90 Suppl 31(Suppl 31):6-12. doi: 10.1177/014107689709031S03.
8
Annual review or continuous assessment?年度评审还是持续评估？
J R Soc Med. 1996;89 Suppl 27(Suppl 27):3-7.
本文引用的文献
1
Failure of ursodeoxycholic acid to dissolve radiolucent gallstones in patients with cystic fibrosis.熊去氧胆酸对囊性纤维化患者中透光性胆结石溶解无效。
Acta Paediatr. 1993 Jun-Jul;82(6-7):562-5. doi: 10.1111/j.1651-2227.1993.tb12754.x.
2
Liver cirrhosis in cystic fibrosis--therapeutic implications and long term follow up.囊性纤维化中的肝硬化——治疗意义及长期随访
Arch Dis Child. 1993 May;68(5):653-7. doi: 10.1136/adc.68.5.653.
3
Effect of ursodeoxycholic acid on intracellular pH in a bile duct epithelium-like cell line.
Hepatology. 1994 Jan;19(1):145-54.
4
Ursodeoxycholic acid reduces the systemic toxicity of 1,2-dichloro,4-nitrobenzene by stimulating hepatic glutathione S-transferase in mice.熊去氧胆酸通过刺激小鼠肝脏谷胱甘肽S-转移酶来降低1,2-二氯-4-硝基苯的全身毒性。
Life Sci. 1994;54(14):983-9. doi: 10.1016/0024-3205(94)00500-1.
5
Ursodeoxycholic therapy in chronic liver disease: a meta-analysis in primary biliary cirrhosis and in chronic hepatitis.
Am J Gastroenterol. 1994 Mar;89(3):392-8.
6
Analysis of risk factors for the development of liver disease associated with cystic fibrosis.囊性纤维化相关肝病发生的危险因素分析。
J Pediatr. 1994 Mar;124(3):393-9. doi: 10.1016/s0022-3476(94)70361-2.
7
Hepatobiliary scintigraphy in children with cystic fibrosis and liver disease.囊性纤维化和肝病患儿的肝胆闪烁显像
J Nucl Med. 1994 Mar;35(3):432-5.
8
Liver transplantation for hepatic cirrhosis in cystic fibrosis.
Arch Dis Child. 1994 Oct;71(4):349-52. doi: 10.1136/adc.71.4.349.
9
Cystic fibrosis gene and mucin secretion.囊性纤维化基因与黏蛋白分泌
Lancet. 1994 Jan 1;343(8888):7. doi: 10.1016/s0140-6736(94)90872-9.
10
An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer.一种通过体细胞基因转移治疗囊性纤维化肝胆疾病的方法。
Proc Natl Acad Sci U S A. 1993 May 15;90(10):4601-5. doi: 10.1073/pnas.90.10.4601.
Zotero 插件